Analyst Price Targets — MLAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 4, 2026 11:32 am | — | Wells Fargo | $94.00 | $87.53 | TheFly | Mesa Labs price target raised to $94 from $83 at Wells Fargo |
| December 15, 2025 11:28 am | — | Wells Fargo | $83.00 | $77.76 | TheFly | Mesa Labs price target raised to $83 from $75 at Wells Fargo |
| August 27, 2024 4:19 pm | Brandon Couillard | Wells Fargo | $120.00 | $140.86 | TheFly | Mesa Labs initiated with an Underweight at Wells Fargo |
| June 7, 2024 8:15 am | Vijay Kumar | Evercore ISI | $120.00 | $104.80 | StreetInsider | Evercore ISI Removes Mesa Laboratories (MLAB) from TAP List |
Latest News for MLAB
LAKEWOOD, Colo. , April 02, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0. 16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.
Mesa Laboratories, Inc. (NASDAQ: MLAB - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $79.16 and traded as high as $82.50. Mesa Laboratories shares last traded at $81.13, with a volume of 99,075 shares traded. Analyst
Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.
Principal Financial Group Inc. lessened its stake in Mesa Laboratories, Inc. (NASDAQ: MLAB) by 66.2% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,065 shares of the medical instruments supplier's stock after selling 19,713 shares during the quarter. Principal Financial Group
Diamond Hill Capital Management Inc. grew its holdings in shares of Mesa Laboratories, Inc. (NASDAQ: MLAB) by 218.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 123,381 shares of the medical instruments supplier's stock after purchasing an additional 84,582
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MLAB.
U.S. House Trading
No House trades found for MLAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.